Cargando…

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer

BACKGROUND: The optimal timing of salvage androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy is controversial. We compared the outcomes of ultra-early versus early salvage ADT. METHODS: Among 855 patients undergoing radical prostatectomy at our institution betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Taguchi, Satoru, Fukuhara, Hiroshi, Azuma, Takeshi, Suzuki, Motofumi, Fujimura, Tetsuya, Nakagawa, Tohru, Ishikawa, Akira, Kume, Haruki, Igawa, Yasuhiko, Homma, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203971/
https://www.ncbi.nlm.nih.gov/pubmed/25323845
http://dx.doi.org/10.1186/1471-2490-14-81
_version_ 1782340475614658560
author Taguchi, Satoru
Fukuhara, Hiroshi
Azuma, Takeshi
Suzuki, Motofumi
Fujimura, Tetsuya
Nakagawa, Tohru
Ishikawa, Akira
Kume, Haruki
Igawa, Yasuhiko
Homma, Yukio
author_facet Taguchi, Satoru
Fukuhara, Hiroshi
Azuma, Takeshi
Suzuki, Motofumi
Fujimura, Tetsuya
Nakagawa, Tohru
Ishikawa, Akira
Kume, Haruki
Igawa, Yasuhiko
Homma, Yukio
author_sort Taguchi, Satoru
collection PubMed
description BACKGROUND: The optimal timing of salvage androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy is controversial. We compared the outcomes of ultra-early versus early salvage ADT. METHODS: Among 855 patients undergoing radical prostatectomy at our institution between 2000 and 2012, we identified 121 with adjuvant-treatment-naïve pT2-4N0M0 prostate cancer who received salvage ADT for biochemical recurrence. These patients were divided into an ultra-early salvage ADT group (n = 51), who started salvage ADT before meeting the standardized definition of biochemical recurrence in Japan (two consecutive prostate-specific antigen [PSA] values ≥0.2 ng/ml), and an early salvage ADT group (n = 70) who started salvage ADT when they met the definition. The ultra-early ADT group consisted of those who started salvage ADT with a single PSA value ≥0.2 ng/ml (n = 30) or with two consecutive PSA values >0.1 ng/ml and rising (n = 21). The primary endpoint was biochemical recurrence after salvage ADT, defined as a single PSA value ≥0.2 ng/ml after PSA nadir following salvage ADT. Secondary endpoints were clinical metastasis and cancer-specific survival. A Cox proportional hazards model was used for multivariate analysis. The median follow-up was 65.5 months. RESULTS: Biochemical recurrence occurred in one patient (2.0%) in the ultra-early group and in 12 (17.1%) in the early salvage ADT group. Multivariate analysis identified ultra-early salvage ADT and preoperative Gleason score ≤7 as independent negative predictors of biochemical recurrence after salvage ADT. Only one patient in the early salvage ADT group developed clinical metastasis to a left supraclavicular lymph node, and no patient died from prostate cancer during follow-up. The major limitations of this study were its retrospective design, selection bias, and the possibility that the ultra-early salvage ADT group may have included patients without biochemical recurrence. CONCLUSIONS: Ultra-early salvage ADT was an independent negative predictor of biochemical recurrence after salvage ADT in post-prostatectomy patients. Further consideration should be given to the use of salvage ADT before meeting the current definition of biochemical recurrence.
format Online
Article
Text
id pubmed-4203971
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42039712014-10-22 Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer Taguchi, Satoru Fukuhara, Hiroshi Azuma, Takeshi Suzuki, Motofumi Fujimura, Tetsuya Nakagawa, Tohru Ishikawa, Akira Kume, Haruki Igawa, Yasuhiko Homma, Yukio BMC Urol Research Article BACKGROUND: The optimal timing of salvage androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy is controversial. We compared the outcomes of ultra-early versus early salvage ADT. METHODS: Among 855 patients undergoing radical prostatectomy at our institution between 2000 and 2012, we identified 121 with adjuvant-treatment-naïve pT2-4N0M0 prostate cancer who received salvage ADT for biochemical recurrence. These patients were divided into an ultra-early salvage ADT group (n = 51), who started salvage ADT before meeting the standardized definition of biochemical recurrence in Japan (two consecutive prostate-specific antigen [PSA] values ≥0.2 ng/ml), and an early salvage ADT group (n = 70) who started salvage ADT when they met the definition. The ultra-early ADT group consisted of those who started salvage ADT with a single PSA value ≥0.2 ng/ml (n = 30) or with two consecutive PSA values >0.1 ng/ml and rising (n = 21). The primary endpoint was biochemical recurrence after salvage ADT, defined as a single PSA value ≥0.2 ng/ml after PSA nadir following salvage ADT. Secondary endpoints were clinical metastasis and cancer-specific survival. A Cox proportional hazards model was used for multivariate analysis. The median follow-up was 65.5 months. RESULTS: Biochemical recurrence occurred in one patient (2.0%) in the ultra-early group and in 12 (17.1%) in the early salvage ADT group. Multivariate analysis identified ultra-early salvage ADT and preoperative Gleason score ≤7 as independent negative predictors of biochemical recurrence after salvage ADT. Only one patient in the early salvage ADT group developed clinical metastasis to a left supraclavicular lymph node, and no patient died from prostate cancer during follow-up. The major limitations of this study were its retrospective design, selection bias, and the possibility that the ultra-early salvage ADT group may have included patients without biochemical recurrence. CONCLUSIONS: Ultra-early salvage ADT was an independent negative predictor of biochemical recurrence after salvage ADT in post-prostatectomy patients. Further consideration should be given to the use of salvage ADT before meeting the current definition of biochemical recurrence. BioMed Central 2014-10-16 /pmc/articles/PMC4203971/ /pubmed/25323845 http://dx.doi.org/10.1186/1471-2490-14-81 Text en © Taguchi et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Taguchi, Satoru
Fukuhara, Hiroshi
Azuma, Takeshi
Suzuki, Motofumi
Fujimura, Tetsuya
Nakagawa, Tohru
Ishikawa, Akira
Kume, Haruki
Igawa, Yasuhiko
Homma, Yukio
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title_full Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title_fullStr Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title_full_unstemmed Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title_short Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
title_sort ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pt2-4n0m0 prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203971/
https://www.ncbi.nlm.nih.gov/pubmed/25323845
http://dx.doi.org/10.1186/1471-2490-14-81
work_keys_str_mv AT taguchisatoru ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT fukuharahiroshi ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT azumatakeshi ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT suzukimotofumi ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT fujimuratetsuya ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT nakagawatohru ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT ishikawaakira ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT kumeharuki ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT igawayasuhiko ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer
AT hommayukio ultraearlyversusearlysalvageandrogendeprivationtherapyforpostprostatectomybiochemicalrecurrenceinpt24n0m0prostatecancer